Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
The American Journal of Managed Care4d
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
FierceBiotech5d
Denali eyes approval after Hunter syndrome drug clears safety measures, reduces biomarkers in open-label study
After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...
FierceBiotech7h
Pfizer's investigational candidate combo cuts prostate cancer progression by 49% in phase 1
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
PharmiWeb12d
Lundbeck announces positive results from 12-month…
Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin ...
Business Wire3d
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug ...
Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...
Multiple Sclerosis News Today4d
Phase 2 trial of obexelimab recruiting adults with relapsing MS
A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...
Greenwich LifeSciences provides update on FLAMINGO-01 open label HLA data
Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...
Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...